Literature DB >> 9131005

Analysis of the coding sequence for the GM-CSF receptor alpha and beta chains in patients with juvenile chronic myeloid leukemia (JCML).

R W Freeburn1, R E Gale, H M Wagner, D C Linch.   

Abstract

Peripheral blood granulocyte-macrophage progenitors (CFU-GMs) from patients with juvenile chronic myeloid leukemia (JCML) are able to proliferate spontaneously in the absence of exogenous growth factors and studies have shown that these progenitors display a hypersensitive growth response to GM-colony-stimulating factors (CSFs) in culture. We screened RNA from six patients with JCML for mutations in the GM-CSF receptor (GM-CSFR) coding sequence using RT-PCR-SSCP. Altered patterns were found in five patients for the GM-CSFR alpha chain, and in five patients for the beta chain. Two nucleotide substitutions accounted for all alpha chain abnormalities; one was conservative for Val333 and the other caused an Ala17-->Gly substitution. Both had previously been detected in normal controls. Sequencing of beta chain abnormalities revealed four base substitutions. Three were previously described polymorphisms, one causing a Pro603-->Thr substitution and two conservative point mutations involving Ser426 and Pro648. A further nucleotide mutation, which resulted in a Glu249-->Gln substitution, was also found but is not thought to be of pathological significance. Polymorphisms of the GM-CSFR alpha and beta chains are common, but pathogenic point mutations of the GM-CSFR are infrequent in patients with JCML and are unlikely to be involved in the hypersensitivity to GM-CSF demonstrated by progenitor cells.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9131005

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  1 in total

1.  Lactation defect in a widely used MMTV-Cre transgenic line of mice.

Authors:  Taichang Yuan; Yongping Wang; Lily Pao; Steve M Anderson; Haihua Gu
Journal:  PLoS One       Date:  2011-04-29       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.